Sutro Biopharma (NASDAQ:STRO) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Sutro Biopharma (NASDAQ:STRO) in a research note released on Wednesday morning, Benzinga reports. They currently have a $12.00 target price on the stock.

STRO has been the topic of several other reports. Oppenheimer reiterated an outperform rating and issued a $10.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, May 15th. Wedbush restated an outperform rating and set a $8.00 price target on shares of Sutro Biopharma in a research report on Tuesday, May 14th. Finally, Bank of America started coverage on Sutro Biopharma in a research report on Wednesday, May 8th. They set a buy rating and a $12.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and an average price target of $12.50.

Sutro Biopharma Trading Up 20.9 %

STRO traded up $0.75 on Wednesday, hitting $4.34. 508,735 shares of the stock traded hands, compared to its average volume of 884,411. Sutro Biopharma has a 52 week low of $2.01 and a 52 week high of $6.13. The firm has a market capitalization of $354.97 million, a PE ratio of -2.07 and a beta of 1.22. The business has a fifty day moving average price of $3.52 and a two-hundred day moving average price of $4.05.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.20. Sutro Biopharma had a negative return on equity of 94.18% and a negative net margin of 74.61%. The company had revenue of $25.71 million for the quarter, compared to analyst estimates of $26.28 million. On average, equities research analysts forecast that Sutro Biopharma will post -3.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its holdings in Sutro Biopharma by 14,125.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock worth $38,000 after buying an additional 8,758 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Sutro Biopharma in the 4th quarter worth $60,000. ProShare Advisors LLC grew its stake in shares of Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after purchasing an additional 5,373 shares during the period. Lazard Asset Management LLC bought a new stake in Sutro Biopharma in the first quarter valued at about $92,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Sutro Biopharma by 24.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after buying an additional 3,578 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.